Molecular Dx test for HAI-causing bacteria gains FDA clearance

07/30/2013 | GenomeWeb Daily News (free registration)

The FDA has cleared IntelligentMDx to market an assay used to detect certain genes linked to vancomycin-resistant enterococci, which can trigger hospital-acquired infections in the bloodstream, surgical wounds and the urinary tract. The assay, which runs on Abbott's m2000 diagnostic platform, takes less than three hours to generate results for as many as 46 samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park